HC Wainwright reiterated their buy rating on shares of ChromaDex (NASDAQ:CDXC - Free Report) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $11.00 target price on the stock.
CDXC has been the topic of several other research reports. StockNews.com lowered shares of ChromaDex from a "strong-buy" rating to a "buy" rating in a research report on Thursday, March 6th. LADENBURG THALM/SH SH boosted their target price on shares of ChromaDex from $6.80 to $8.10 and gave the company a "buy" rating in a report on Wednesday, March 5th.
View Our Latest Research Report on CDXC
ChromaDex Price Performance
The business's fifty day moving average price is $6.16 and its two-hundred day moving average price is $5.44. ChromaDex has a 12 month low of $2.31 and a 12 month high of $9.18. The company has a market cap of $611.50 million, a P/E ratio of 787.29 and a beta of 2.21.
Hedge Funds Weigh In On ChromaDex
A number of large investors have recently modified their holdings of CDXC. USA Financial Formulas purchased a new stake in ChromaDex in the 4th quarter worth approximately $25,000. State of Wyoming purchased a new stake in shares of ChromaDex in the fourth quarter worth $39,000. Mercer Global Advisors Inc. ADV bought a new stake in ChromaDex during the fourth quarter valued at $53,000. Truist Financial Corp purchased a new position in ChromaDex during the fourth quarter worth about $54,000. Finally, FMR LLC bought a new position in ChromaDex in the 3rd quarter worth about $55,000. 15.41% of the stock is currently owned by institutional investors.
About ChromaDex
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Read More
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
